Incyte Corp (NASDAQ:INCY)
| 22.17 Data as of May 23 |  -0.15 / -0.67%Today’s Change | 15.43 Today|||52-Week Range 26.30 | +33.47% Year-to-Date |
Latest INCY News | Press Releases
No recent news for Incyte Corp.
Today’s Trading
| Previous close | 22.32 |
| Today’s open | 22.11 |
| Day’s range | 21.56 - 22.69 |
| Volume | 1,270,757 |
| Average volume (3 months) | 1,270,480 |
| Market cap | $3.0B |
| Dividend yield | -- |
Data as of 4:00pm ET, 05/23/2013
Growth & Valuation
| Earnings growth (last year) | +77.18% |
| Earnings growth (this year) | +70.63% |
| Earnings growth (next 5 years) | +119.62% |
| Revenue growth (last year) | +214.50% |
| P/E ratio | NM |
| Price/Sales | 7.25 |
| Price/Book | -- |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| TAROTaro Pharmaceutical ... | -0.60 | -0.94% |
| UTHRUnited Therapeutics ... | -0.21 | -0.31% |
| MYGNMyriad Genetics Inc | -0.05 | -0.16% |
| THRXTheravance Inc | +0.57 | +1.57% |
Data as of 4:04pm ET, 05/23/2013
Financials
| Next reporting date | August 1, 2013 |
| EPS forecast (this quarter) | $0.08 |
| Annual revenue (last year) | $297.1M |
| Annual profit (last year) | -$44.3M |
| Net profit margin | -14.92% |
Profile
Sector Health Technology |
Industry Biotechnology |
Chief Financial Officer & Executive Vice President David C. Hastings, CPA |
EVP, Chief Drug Development & Medical Officer Richard S. Levy, MD |
Corporate headquarters Wilmington, Delaware |
Forecasts
